Wells Fargo & Company Cuts Incyte (NASDAQ:INCY) Price Target to $101.00

robot
Abstract generation in progress

Wells Fargo & Company has lowered its price target for biopharmaceutical company Incyte (NASDAQ:INCY) from $107 to $101, maintaining an “equal weight” rating. This decision follows Incyte’s Q4 earnings, which showed a revenue beat but an EPS miss, along with a softer 2026 revenue outlook and concerns regarding its drug Opzelura and Jakafi’s patent and generic exposure. Despite institutional investors holding a large stake, insiders have recently sold a significant number of shares.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский язык
  • Français
  • Deutsch
  • Português (Portugal)
  • ภาษาไทย
  • Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)